Sanchez-Bilbao, L.Loricera, J.Castaneda, S.Moriano, C.Narvaez, J.Aldasoro, V.Maiz, O.Melero, R.Villa-Blanco, I.Vela-Casasempere, P.Romero-Yuste, S.Callejas-Rubio, J. L.De Miguel, E.Galindez-Agirregoikoa, E.Sivera, F.Fernandez-Lopez, C.Galisteo, C.Ferraz-Amaro, I.Sanchez-Martin, J.Calderon-Goercke, M.Hernandez, J. L.Gonzalez-Gay, M. A.Blanco, R.2023-05-032023-05-032022-06-010003-4967http://hdl.handle.net/10668/20096enINTRAVENOUS VERSUS SUBCUTANEOUS TOCILIZUMAB IN A SERIES OF 471 PATIENTS WITH GIANT CELL ARTERITISconference outputopen access10.1136/annrheumdis-2022-eular.32601468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/379.2.full.pdf850279001211